Trial Profile
A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Proteinuria
- Focus Therapeutic Use
- Acronyms DIAMOND
- 01 Aug 2021 Results of post-hoc exploratory analysis of three randomized studies (DELIGHT (NCT02547935), IMPROVE (Netherlands Trial Register NTR4439) and DIAMOND (NCT03190694)) published in the Diabetes, Obesity and Metabolism.
- 15 Feb 2021 Primary endpoint has not been met. (Change in 24-hr proteinuria with dapagliflozin for six weeks relative to placebo in patients with non-diabetic kidney disease and proteinuria 500 mg/day on stable angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment.), as per published in the Clinical Pharmacokinetics
- 15 Feb 2021 Results (n=48) assessing pharmacokinetic profile of dapagliflozin in patients with chronic kidney disease without type 2 diabetes, published in the Clinical Pharmacokinetics